Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C20H26N4O4 |
Molar mass | 386.452 g·mol−1 |
3D model ( JSmol) | |
| |
|
Bevenopran ( INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. [1] [2] [3] It reached phase III clinical trials for this indication before being discontinued. [4] [5]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C20H26N4O4 |
Molar mass | 386.452 g·mol−1 |
3D model ( JSmol) | |
| |
|
Bevenopran ( INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. [1] [2] [3] It reached phase III clinical trials for this indication before being discontinued. [4] [5]